Apeiron acquires rights for Phase III immunotherapy against high-risk neuroblastoma from CCRI and SIOPEN

APEIRON Biologics AG (Apeiron) today announced the signing of agreements with the Children’s Cancer Research Institute, Vienna (CCRI) and the European Neuroblastoma Research Network (SIOPEN) that grant Apeiron the rights to further develop and commercialize the monoclonal antibody ch14.18 together with these groups. This antibody presently is being investigated by CCRI and SIOPEN in a Phase III study in high-risk neuroblastoma patients in many centers in Europe. Production is contracted to Polymun Scientific.

Press release